| 1 |
28319085 | Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. | 2017 May |
1 |
| 2 |
26987906 | High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia. | 2016 Jun |
1 |
| 3 |
26473951 | Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release. | 2015 |
1 |
| 4 |
24088895 | Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib. | 2014 Jan 1 |
1 |
| 5 |
24504921 | Ageing is a risk factor in imatinib mesylate cardiotoxicity. | 2014 Apr |
1 |
| 6 |
23613979 | Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation. | 2013 |
1 |
| 7 |
22211240 | Alternative splicing of apoptosis-related genes in imatinib-treated K562 cells identified by exon array analysis. | 2012 Apr |
1 |
| 8 |
21115411 | Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. | 2011 Feb |
2 |
| 9 |
20094798 | Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. | 2010 May |
1 |
| 10 |
20723293 | [Effects of STI571 combined with As₂O₃ on proliferation, apoptosis and caspase 3, Bcl-xL expression of K562 cells]. | 2010 Aug |
3 |
| 11 |
19934315 | Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity. | 2009 Dec 15 |
1 |
| 12 |
17420275 | GATA-1 and Gfi-1B interplay to regulate Bcl-xL transcription. | 2007 Jun |
1 |
| 13 |
17545631 | BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. | 2007 Jun 1 |
1 |
| 14 |
17926190 | (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells. | 2007 Nov |
1 |
| 15 |
18088462 | [STI571 induces apoptosis of K562 cells through down-regulation of anti-apoptotic protein Mcl-1 and Bcl-xl expression]. | 2007 Dec |
3 |
| 16 |
15039284 | Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. | 2004 Jul 15 |
1 |
| 17 |
11782377 | Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. | 2002 Jan 1 |
1 |
| 18 |
12231544 | Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. | 2002 Sep |
1 |
| 19 |
11179439 | The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. | 2001 Mar |
1 |
| 20 |
11313280 | Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. | 2001 May 1 |
1 |
| 21 |
11368438 | Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. | 2001 May |
1 |
| 22 |
10815921 | The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. | 2000 May |
1 |